Stephanie Fradette

Company: Biogen

Job title: VP, Head of Neuromuscular Development Unit

Seminars:

Panel Discussion: Striving for Consensus on the Level of Evidence Required for Approval 10:45 am

How can we best reconcile the variance in acceptable measures of ALSFRS-R decline across geographies to get drugs to patients faster? How does the level of evidence required for accelerated approval vary in familial vs sporadic ALS? When are expanded access programs deemed acceptable ahead of final study results? If there’s going to be a…Read more

day: Day Two Track B AM

Panel Discussion: Promoting Earlier Commercial Discussions to Accelerate the Post-Approval Path to Market 9:00 am

What must be considered when deciphering commercially viable targets for ALS? How can we ensure access to promising, yet expensive, ALS treatments to patients who really need them? Why is it important to assess market viability during the early stages of initial R&D discussions?Read more

day: Day Two AM